thalidomide has been researched along with Sleep Initiation and Maintenance Disorders in 11 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Sleep Initiation and Maintenance Disorders: Disorders characterized by impairment of the ability to initiate or maintain sleep. This may occur as a primary disorder or in association with another medical or psychiatric condition.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We completed a two-stage Phase II dose titration study of thalidomide, the primary purpose of which was to assess appetite response to thalidomide in cancer-associated anorexia." | 9.16 | A Phase II dose titration study of thalidomide for cancer-associated anorexia. ( Bicanovsky, L; Davis, M; Lagman, R; Lasheen, W; Mahmoud, F; Walsh, D, 2012) |
| "We completed a two-stage Phase II dose titration study of thalidomide, the primary purpose of which was to assess appetite response to thalidomide in cancer-associated anorexia." | 5.16 | A Phase II dose titration study of thalidomide for cancer-associated anorexia. ( Bicanovsky, L; Davis, M; Lagman, R; Lasheen, W; Mahmoud, F; Walsh, D, 2012) |
| "Thalidomide has proven its efficacy in refractory cutaneous lupus disease, although it is not exempt from significant side effects and frequent relapses after withdrawal." | 2.77 | Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. ( Ávila, G; Cortés-Hernández, J; Ordi-Ros, J; Vilardell-Tarrés, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (54.55) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Cowan, TL | 1 |
| Wilson, A | 1 |
| Murrell, DF | 1 |
| Davis, M | 1 |
| Lasheen, W | 1 |
| Walsh, D | 1 |
| Mahmoud, F | 1 |
| Bicanovsky, L | 1 |
| Lagman, R | 1 |
| Cortés-Hernández, J | 1 |
| Ávila, G | 1 |
| Vilardell-Tarrés, M | 1 |
| Ordi-Ros, J | 1 |
| NULSEN, RO | 1 |
| COHEN, S | 1 |
| SKRE, H | 1 |
| MATTHEWS, V | 1 |
| LEHMANN, HE | 1 |
| BAN, TA | 1 |
| LASAGNA, L | 1 |
| MANDARINO, MP | 1 |
| Schulte-Wissermann, H | 1 |
| Fox, MR | 1 |
| Harris, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study To Evaluate The Safety And Efficacy Of Lenalidomide For The Treatment Of Refractory Cutaneous Lupus[NCT01408199] | Phase 4 | 15 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for thalidomide and Sleep Initiation and Maintenance Disorders
| Article | Year |
|---|---|
A Phase II dose titration study of thalidomide for cancer-associated anorexia.
Topics: Aged; Anorexia; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Female; Humans; | 2012 |
Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus.
Topics: Administration, Oral; Adult; Diarrhea; Drug Resistance; Female; Humans; Immunologic Factors; Lenalid | 2012 |
9 other studies available for thalidomide and Sleep Initiation and Maintenance Disorders
| Article | Year |
|---|---|
Mental health, insomnia and suicidal ideation during treatment with apremilast.
Topics: Humans; Mental Health; Risk Factors; Sleep Initiation and Maintenance Disorders; Suicidal Ideation; | 2022 |
Trial of thalidomide in insomnia associated with the third trimester.
Topics: Female; Humans; Hypnotics and Sedatives; Pregnancy; Pregnancy Complications; Pregnancy Trimester, Th | 1961 |
Sleep regulation with thalidomide.
Topics: Anesthesia; Hypnotics and Sedatives; Sleep; Sleep Initiation and Maintenance Disorders; Thalidomide | 1960 |
[THALIDOMIDE POLYNEURITIS: A FORM OF RIBOFLAVIN AVITAMINOSIS?].
Topics: Avitaminosis; Dermatology; Drug Hypersensitivity; Edema; Folic Acid; Geriatrics; Headache; Neuritis; | 1963 |
A COMPARATIVE STUDY OF THIRTEEN HYPNOTIC DRUGS.
Topics: Barbiturates; Biomedical Research; Chloral Hydrate; Chlorprothixene; Ethchlorvynol; Glutethimide; Hu | 1964 |
Thalidomide--a new nonbarbiturate sleep--inducing drug.
Topics: Anesthesia; Hypnotics and Sedatives; Sleep; Sleep Initiation and Maintenance Disorders; Thalidomide | 1960 |
Thalidomide in the treatment of insomnia: a study of its use in 87 orthopaedic patients.
Topics: Anesthesia; Hypnotics and Sedatives; Orthopedic Procedures; Orthopedics; Sleep Initiation and Mainte | 1961 |
[The Contergan (Thalidomide) case. Catastrophic consequences].
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Female; Humans; Hypnotics and Sedatives; Infan | 2000 |
Intractable insomnia after cessation of treatment with thalidomide.
Topics: Aged; Crohn Disease; Humans; Male; Sleep Initiation and Maintenance Disorders; Thalidomide | 2001 |